00:00 / 27:30
#1 Valuing innovation and introducing Brennus Pharma's in vivo immunotherapies.
#1
Valuing innovation and introducing Brennus Pharma's in vivo immunotherapies.
#2
Abivax's first-in-class molecule and managing economic environments.
03:12
#3
Prioritization and de-risking breakthrough science for investment funds.
04:11
#4
The critical role of Chemistry, Manufacturing, and Controls in early drug development.
06:22
#5
Private versus public funding and the transition to the stock market.
09:15
#6
The strategic mistake of building a biotech company solely to sell it.
11:56
#7
The necessity of raising capital in the US and the Nasdaq milestone.
15:40
#8
Managing down rounds, dilution, and protecting company valuation.
19:23
#9
The power of extreme focus and optimal resource allocation in biotech.
23:09
#10
Key takeaways and teasing the final episode of the execution series.
26:41
"Executing differently takes courage" (4/5) - Biotech survival and resource allocation : why execution is about choosing what not to do
You can have the best science in the world, but it means nothing if your company runs out of cash. When resources are limited and markets are unforgiving, execution ceases to be a management theory. It becomes a strict matter of survival. What does it actually cost to fund biotech innovation without losing control of your clinical vision?
Welcome to Pharma Minds, Summer Series "Executing differently takes courage". I wanted to place this conversation fourth in this miniseries because it captures the absolute moment of truth in execution. When science is not enough and resources are scarce, every decision can dictate whether a company lives or dies. In early-stage biotech, executing is deeply radical. It is about choosing, accepting what you will not do, and holding that line. After looking at markets and systems in earlier episodes, we have reached the barest level of execution: two leaders, pure science, and the cold reality of how we fund what we believe in.
In this episode, I sit down with Marc de Garidel, CEO of Abivax, and Paul Bravetti, CEO of Brenus Pharma. From late-stage clinical phase trials to highly complex first-in-human oncology immunotherapies, they share their impossible context: navigating environments where capital is tight, valuation paradigms have shifted, and strict focus is the only strategy that works. They break down what it takes to execute safely and scale disruptive science.
In this episode, we cover:
◾️The Survival Discipline : Why execution in biotech means ruthless prioritization and strict cost control.
◾️Valuing Innovation : Anticipating regulatory milestones and de-risking science early to attract investors.
◾️The Manufacturing Trap : How Chemistry, Manufacturing, and Controls (CMC) can make or break a clinical asset.
◾️Financing Strategy : Timing your private rounds, handling market downturns, and the leap to the Nasdaq.
◾️The Exit Illusion : Why building a company just to sell it is a mistake, and how developing a great drug attracts buyers naturally.
The rules of biotech are stark. Focus creates value. Distraction destroys it. You protect the science by making hard decisions early.
👉 What is the hardest trade-off you have had to make when allocating resources to a new project? Let us know in the comments.
Science starts the journey. Execution secures the funding.
If you want to follow the whole series, don't forget to subscribe.
-
This episode has been translated with the help of AI tools and edited to align with the editorial direction of this series.
Originally released on: 26/01/2026.
To listen to the original French version of this episode: https://smartlink.ausha.co/pharma-minds/50-batir-une-biotech-a-succes-decisions-cles-arbitrages-et-erreurs-a-eviter-table-ronde-avec-marc-de-garidel-paul.
Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.
Powered by Ausha 🚀